Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Benefits of an experimental program of equestrian therapy for children with ADHD.

García-Gómez A, Rodríguez-Jiménez M, Guerrero-Barona E, Rubio-Jiménez JC, García-Peña I, Moreno-Manso JM.

Res Dev Disabil. 2016 Dec;59:176-185. doi: 10.1016/j.ridd.2016.09.003. Epub 2016 Sep 7.

PMID:
27614276
2.

The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.

Paíno T, Garcia-Gomez A, González-Méndez L, San-Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho D, Ortiz-de-Solorzano C, Corchete LA, Gutiérrez NC, Maetos MV, Garayoa M, Ocio EM.

Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20.

PMID:
27440267
3.

DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes.

Vento-Tormo R, Álvarez-Errico D, Garcia-Gomez A, Hernández-Rodríguez J, Buján S, Basagaña M, Méndez M, Yagüe J, Juan M, Aróstegui JI, Ballestar E.

J Allergy Clin Immunol. 2017 Jan;139(1):202-211.e6. doi: 10.1016/j.jaci.2016.05.016. Epub 2016 Jul 7.

PMID:
27394913
4.

Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.

Herrero AB, García-Gómez A, Garayoa M, Corchete LA, Hernández JM, San Miguel J, Gutierrez NC.

Am J Pathol. 2016 Aug;186(8):2171-82. doi: 10.1016/j.ajpath.2016.04.003. Epub 2016 Jun 11.

PMID:
27301357
5.

The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis.

Gómez-Del Arco P, Perdiguero E, Yunes-Leites PS, Acín-Pérez R, Zeini M, Garcia-Gomez A, Sreenivasan K, Jiménez-Alcázar M, Segalés J, López-Maderuelo D, Ornés B, Jiménez-Borreguero LJ, D'Amato G, Enshell-Seijffers D, Morgan B, Georgopoulos K, Islam AB, Braun T, de la Pompa JL, Kim J, Enriquez JA, Ballestar E, Muñoz-Cánoves P, Redondo JM.

Cell Metab. 2016 May 10;23(5):881-92. doi: 10.1016/j.cmet.2016.04.008.

PMID:
27166947
6.

Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus.

Martínez I, García-Carpizo V, Guijarro T, García-Gomez A, Navarro D, Aranda A, Zambrano A.

Virulence. 2016 May 18;7(4):427-42. doi: 10.1080/21505594.2016.1144001. Epub 2016 Jan 25.

7.

Constant capacitance in nanopores of carbon monoliths.

García-Gómez A, Moreno-Fernández G, Lobato B, Centeno TA.

Phys Chem Chem Phys. 2015 Jun 28;17(24):15687-90. doi: 10.1039/c5cp01904d. Epub 2015 Jun 1.

PMID:
26028487
8.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators..

Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13.

9.

NF-κB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation.

de la Rica L, García-Gómez A, Comet NR, Rodríguez-Ubreva J, Ciudad L, Vento-Tormo R, Company C, Álvarez-Errico D, García M, Gómez-Vaquero C, Ballestar E.

Genome Biol. 2015 Jan 5;16:2. doi: 10.1186/s13059-014-0561-5.

10.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

11.

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF, Garayoa M.

World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. Review.

12.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.

Leukemia. 2015 Mar;29(3):705-14. doi: 10.1038/leu.2014.238. Epub 2014 Aug 8.

PMID:
25102946
13.

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M.

Clin Cancer Res. 2014 Mar 15;20(6):1542-54. doi: 10.1158/1078-0432.CCR-13-1657. Epub 2014 Jan 31.

14.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators..

N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673.

15.

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M.

Invest New Drugs. 2013 Feb;31(1):200-5. doi: 10.1007/s10637-012-9845-3. Epub 2012 Jul 7.

PMID:
22773056
16.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

17.

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.

Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, Lee FY, Pandiella A, San Miguel JF, Garayoa M.

PLoS One. 2012;7(4):e34914. doi: 10.1371/journal.pone.0034914. Epub 2012 Apr 23.

18.

Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons.

García-Escudero V, García-Gómez A, Langa E, Martín-Bermejo MJ, Ramírez-Camacho R, García-Berrocal JR, Moreno-Flores MT, Avila J, Lim F.

Neurosci Lett. 2012 Feb 10;509(1):27-32. doi: 10.1016/j.neulet.2011.12.037. Epub 2011 Dec 31.

PMID:
22227621
19.

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

de Queiroz Crusoe E, Maiso P, Fernandez-Lazaro D, San-Segundo L, Garayoa M, Garcia-Gomez A, Gutierrez NC, Delgado M, Colado E, Martin-Sanchez J, Lee FY, Ocio EM.

Ann Hematol. 2012 Feb;91(2):257-69. doi: 10.1007/s00277-011-1287-z. Epub 2011 Jul 1.

PMID:
21720745
20.

Expression of plasminogen activator inhibitor-1 by olfactory ensheathing glia promotes axonal regeneration.

Simón D, Martín-Bermejo MJ, Gallego-Hernández MT, Pastrana E, García-Escudero V, García-Gómez A, Lim F, Díaz-Nido J, Avila J, Moreno-Flores MT.

Glia. 2011 Oct;59(10):1458-71. doi: 10.1002/glia.21189. Epub 2011 May 27.

PMID:
21626571

Supplemental Content

Loading ...
Support Center